Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a(542 views) Lanzillo R, Carbone F, Quarantelli M, Bruzzese D, Carotenuto A, De RosaV, Colamatteo A, Micillo T, De Luca Picione C, Saccà F, De Rosa A, Moccia M, Brescia Morra V, Matarese G
Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche, Universita degli Studi di Napoli "Federico II", Napoli, Italy.
Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), Napoli, Italy.
Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Napoli, Italy.
Dipartimento di Sanita Pubblica, Universita degli Studi di Napoli "Federico II", Napoli, Italy.
Dipartimento di Biologia, Universita degli Studi di Napoli "Federico II", Napoli, Italy.
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Universita degli Studi di Napoli "Federico II", Napoli, Italy. Electronic address: giuseppe.matarese@unina.it.
References: Not available.
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a
Reliable immunologic biomarkers able to monitor disease course during
multiple sclerosis (MS) are still missing. We aimed at identifying
possible immunometabolic biomarkers able to predict the clinical outcome
in MS patients during treatment with interferon (IFN)-beta-1a. We
measured in 45 relapsing-remitting (RR) MS patients, blood circulating
levels of several immunometabolic markers, at enrolment, and correlated
their levels to disease activity and progression over time. Higher
levels of interleukin (IL)-6, soluble-CD40-ligand (sCD40L) and leptin at
baseline associated with a higher relapse rate and a greater risk of
experiencing at least one relapse in the following year. Higher values
of soluble tumor necrosis factor receptor (sTNF-R) and leptin at
baseline were predictive of a higher number of lesions in the following
one-year of follow up. In conclusion, our data suggest that an
immunometabolic profiling measuring IL-6, sCD40L, leptin and sTNF-R at
baseline, could represent a useful tool to predict disease course in
RRMS patients during treatment with IFN-beta-1a.
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a